Related Articles

Classification of non-Hodgkin’s lymphoma.

Hematol Oncol Clin North Am. 2008 Oct;22(5):781-805, vii

Authors: Good DJ, Gascoyne RD

This article provides an overview of the pathology and classification of non-Hodgkin lymphomas. Key histologic features are described for the common entities including both B-cell and T/NK-cell lineages. Additionally, details of the characteristic immunophenotypic findings, molecular genetic results, and common or clinically relevant cytogenetic alterations are described. Helpful tables are included that outline the key diagnostic features.

PMID: 18954737 [PubMed - indexed for MEDLINE]

[Read more →]

Related Articles

Staging and evaluation of the patient with lymphoma.

Hematol Oncol Clin North Am. 2008 Oct;22(5):825-37, vii-viii

Authors: Cheson BD

Patients who have non-Hodgkin’s lymphoma or Hodgkin lymphoma most often present for medical attention because of signs or symptoms referable to enlarged lymph nodes or other disease-related symptoms (such as fevers, night sweats or fatigue). Less often, enlarged lymph nodes or splenomegaly may be incidental findings during evaluation for other medical issues. Determination of the extent of disease and accurate assessment of responses are necessary for appropriate management. Newer technologies have improved the ability to evaluate patients and to conduct clinical trials, leading to more effective therapies. This article addresses the advances in staging and evaluation of patients who have lymphoma, specifically examining the use of positron emission tomography.

PMID: 18954739 [PubMed - indexed for MEDLINE]

[Read more →]

Related Articles

Marginal zone lymphomas.

Hematol Oncol Clin North Am. 2008 Oct;22(5):883-901, viii

Authors: Zucca E, Bertoni F, Stathis A, Cavalli F

In the World Health Organization classification of tumors of hematopoietic and lymphoid tissues, the group of marginal zone lymphomas comprises three different entities, namely the extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, the nodal marginal zone B-cell, and the splenic marginal zone B-cell lymphoma (with or without circulating villous lymphocytes). This article addresses each of the marginal zone lymphomas.

PMID: 18954742 [PubMed - indexed for MEDLINE]

[Read more →]

Related Articles

Indolent lymphomas other than follicular and marginal zone lymphomas.

Hematol Oncol Clin North Am. 2008 Oct;22(5):903-40, viii

Authors: Peinert S, Seymour JF

This article addresses two of the less common entities among clinically indolent B-cell non-Hodgkin lymphomas: small lymphocytic lymphoma and lymphoplasmacytic lymphoma, also known as “Waldenstrom’s macroglobulinemia.” Differential diagnoses and prognostic factors are discussed for each as well as new treatment options and stem cell transplantation.

PMID: 18954743 [PubMed - indexed for MEDLINE]

[Read more →]

Related Articles

Diffuse large B-cell lymphoma.

Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix

Authors: Friedberg JW, Fisher RI

Diffuse large B-cell lymphoma (DLBCL) remains a curable lymphoma, with improved outcome resulting in large part from the incorporation of rituximab in standard regimens. The disease is heterogeneous clinically, morphologically, and molecularly. Recent insights into the molecular heterogeneity of DLBCL are beginning to yield novel therapeutics with significant promise for key subsets of patients. Although cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone chemotherapy with rituximab remains a standard therapeutic approach for most patients who have DLBCL, it is anticipated that novel agents will be included in treatment regimens for many patients in the near future.

PMID: 18954744 [PubMed - indexed for MEDLINE]

[Read more →]

Related Articles

Therapy of mantle cell lymphoma: current standards and future strategies.

Hematol Oncol Clin North Am. 2008 Oct;22(5):953-63, ix

Authors: Schmidt C, Dreyling M

Mantle cell lymphoma is characterized clinically by an aggressive clinical course and is relatively resistant to conventional chemotherapies. When in its advanced stages, currently available immunochemotherapy regimens remain noncurative despite high initial response rates. In contrast, consolidating high-dose therapy with autologous stem cell retransfusion significantly extends progression-free survival of young patients. Currently, allogenic bone marrow transplantation represents the only therapy with the potential for a curative approach, although associated with a high rate of complications. New concepts of therapy are urgently warranted, including new molecular approaches, such as bortezomib, thalidomide, lenalidomide, and temsirolimus.

PMID: 18954745 [PubMed - indexed for MEDLINE]

[Read more →]

Related Articles

Highly aggressive lymphomas in adults.

Hematol Oncol Clin North Am. 2008 Oct;22(5):965-78, ix

Authors: Sweetenham JW

Highly aggressive lymphomas are relatively uncommon in adults, comprising approximately 4% to 5% of all non-Hodgkin lymphomas in the United States and Western Europe. The designation of “highly aggressive” is generally restricted to precursor T-cell and B-cell lymphoblastic lymphoma/leukemia and Burkitt’s lymphoma/leukemia. Treatment strategies for lymphoblastic lymphoma and Burkitt’s lymphoma include complex, highly intensive combination chemotherapy regimens, which may be curative. As with other subtypes of NHL, emerging data from gene-expression profiling and related techniques are helping to define these entities more precisely and identify potential new rational therapeutic targets.

PMID: 18954746 [PubMed - indexed for MEDLINE]

[Read more →]